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http://www.biomedcentral.com/1472-6963/14/632RESEARCH ARTICLE Open AccessHospital bed occupancy for rotavirus and all cause
acute gastroenteritis in two Finnish hospitals
before and after the implementation of the
national rotavirus vaccination program with
RotaTeq®
Susanne Hartwig1*, Matti Uhari2, Marjo Renko2, Perrine Bertet1, Maria Hemming3 and Timo Vesikari3Abstract
Background: Vaccination-impact studies of the live-attenuated pentavalent oral vaccine Rotateq® have demonstrated
that the burden of rotavirus gastroenteritis has been reduced significantly after the introduction of RotaTeq®
vaccination, but less is known about the benefit of this vaccination on hospital overcrowding.
Methods: As part of an observational surveillance conducted during the RV seasons 2000/2001 to 2011/2012, we
analysed hospital discharge data collected retrospectively from two Finnish hospitals (Oulu and Tampere), concerning
ICD 10 codes A00-09 (acute gastroenteritis, AGE) and A08.0 (rotaviral acute gastroenteritis RV AGE). We estimated the
reduction in the number of beds occupied and analysed the bed occupancy rate, for RV AGE and all cause AGE, among
0–16 year-old children, before and after the implementation of the RV immunisation program.
Results: The rate of bed days occupied for RV AGE was reduced by 86% (95% CI 66%-94%) in Tampere and 79%
(95% CI 47%-92%) in Oulu after RV vaccination implementation. For all cause AGE, reduction was 50% (95% CI 29% to
65%) in Tampere and 70% (95% CI 58% to 79%) in Oulu. Results were similar among 0–2 year-old children. This effect
was also observed on overcrowding in both hospitals, with a bed occupancy rate for all cause AGE >25% in only 1% of
the time in Tampere and 9% in Oulu after the implementation of the immunisation program, compared to 13%
and 48% in the pre-vaccination period respectively. After extrapolation to the whole country, the annual number of
prevented hospitalizations for all cause AGE in the post-vaccination period in Finland was estimated at 1,646 and 2,303
admissions for 0–2 and 0–16 year-old children respectively.
Conclusions: This study demonstrated that universal RV vaccination is associated with a clear decrease in the number
of bed days and occupancy rates for RV AGE and all cause AGE. Positive consequences include increase in quality of
care and a better healthcare management during winter epidemics.Background
In the pre-vaccination era rotavirus (RV) has been esti-
mated to be responsible for two thirds of hospitalizations
and emergency department consultations for acute gastro-
enteritis (AGE) in children [1] and it was estimated that
RV infections lead to a yearly average of about 700,000* Correspondence: shartwig@spmsd.com
1Epidemiology Department, Sanofi Pasteur MSD, Lyon, France
Full list of author information is available at the end of the article
© 2014 Hartwig et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.outpatient visits, more than 87,000 hospitalizations and
231 death in Europe [2].
Seasonal peaks of RV gastroenteritis occur yearly from
November to May [3] and coincide in many countries with
other winter epidemics such as bronchiolitis due to respira-
tory syncytial virus (RSV) and influenza [4-7] (Figure 1),
leading potentially to overcrowding with increased risks for
nosocomial infections and lessened quality of patient care.
In the literature rotavirus has been repeatedly mentioned asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Coincidence of rotavirus, RSV and influenza from national surveillance data in Finland. From THL: http://www3.thl.fi/stat/.
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season [3,6,7].
The live-attenuated pentavalent oral vaccine Rotateq®
was licensed in 2006. Postlicensure studies have shown
high vaccine effectiveness in preventing hospitalization for
RV gastroenteritis in the field, ranging from 83% to 98%
[8-11], and consistent with pre-licensure efficacy results.
Furthermore, vaccination-impact studies have demon-
strated that the burden of rotavirus gastroenteritis has
been reduced significantly after the introduction of
RotaTeq® vaccination. Evidence included reductions in
healthcare utilization due to RV AGE (hospitalizations
and emergency-department visits reduced by up to 90%),
reductions in the magnitude and duration of the RV
season as assessed by laboratory testing for RV, and the
possible induction of herd immunity [12].
Less is known about the benefit of the implementation
of immunization programs with Rotateq® to avoid situa-
tions of seasonal hospital overcrowding. Several studies
have been conducted to evaluate overcrowding associated
with AGE in emergency departments [13,14], with one
study specifically assessing the workload in pediatric
emergency units during the epidemic season [15], no
study to our knowledge has measured seasonal hospital
disruption due to RV gastroenteritis.
Several indicators have been studied to estimate emer-
gency department crowding and two scales for quantifying
crowding in emergency departments have been developed:
NEDOCS and EDWIN [16-19]. However, no consensus
and no indicators have been developed to measure hos-
pital disruption. We propose to use bed occupancy rates
as a proxy to assess situations of hospital overcrowding.
A prospective surveillance study was established in
2009 at two University hospitals in Finland (Tampere
and Oulu) to document the number of cases of pediatric
AGE requiring hospitalization, and the role of rotavirusand specific serotypes in those cases in the first three years
after the implementation of the universal vaccination
program with RotaTeq®. The study showed that after the
implementation of universal RotaTeq® vaccination, RV
AGE was virtually eliminated among children age-eligible
for the vaccination program [11].
In the frame of this study, a retrospective analysis of the
discharge database was performed to evaluate the impact
of the introduction of RV vaccines into the national vac-
cination program on the rotavirus infections at hospitals.
The aim of the present analysis was to evaluate the bene-
fit of the implementation of the National Immunization
Program with Rotateq® to avoid situations of seasonal hos-
pital overcrowding.
Methods
The study was conducted in accordance with the Declar-
ation of Helsinki, Good Pharmacoepidemiology Practice
guidelines and local laws, rules and regulations. The eth-
ics committee of Pirkanmaa Hospital District (Tampere)
reviewed and approved the study protocol and amend-
ments. The study was also approved by the head of each
hospital.
In the frame of an observational surveillance study
published elsewhere [11], hospital discharge data were
retrospectively collected from Tampere and Oulu hospi-
tals. We further analyzed the data of this retrospective
study part for the RV seasons 2000/2001 to 2011/2012.
The following information was extracted from the hospital
information systems (discharge registers) and analyzed:
ICD 10 codes A00-09 (all codes for intestinal infectious
diseases), A08.0 (rotaviral enteritis).
Admission and discharge dates were used to calculate
the number of beds occupied daily by infants and children
diagnosed with RV AGE and all cause AGE (including RV
AGE) during the RV seasons 2000/2001 to 2011/2012. In
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hospital unit to another, or if a second admission occurred
less than 14 days after a first discharge and if both
admissions were coded with different ICD discharge codes
(among A00-A09), one of them being A08.0 (the code for
RV AGE), this one was selected as this code was only
allocated in case of positive routine laboratory ELISA test
result. In addition to clinical diagnostic, some samples are
sometimes taken as part of the usual care of patients in
both hospitals. In this case, PCR was done to identify pre-
cisely the type of RV causing the disease. Consequently,
most reliable figures are the all cause AGE which do not
depend on local diagnostic and testing practices.
The 0–16 year age group was chosen to follow hospital
admissions including age groups not targeted by the
vaccination, but who may be subject to herd immunity.
The period of 2000/01 to 2005/06 was considered as
the pre-vaccination period, the period of 2006/07 to
2008/09 as a transition period during which both rota-
virus vaccines (RotaTeq® and Rotarix®) were available in
Finland, but with lower coverage rates (reaching 30-35%)
[20], as the vaccines were not included into the national
vaccination program. Universal routine vaccination against
RV AGE was started in Finland on September 1st, 2009
and the period of 2009/10 to 2011/12 was thus considered
as post-vaccination period. Each season started the 1st of
September and ended the 31th of August of the following
year.
The total number of bed days for RV AGE and for all
cause AGE was reported by vaccination periods and
seasons for each hospital. To assess the impact of the
national RV vaccination program, two statistics were
calculated. The first was the relative reduction of the
annual number of bed days between the post- and pre-
vaccination periods, and the second was the absolute
reduction (difference) (95% CI) of the number of bed
days, based on a vaccine probe approach [21]. For both
estimates, we calculated 95% confidence interval (CI)
based on the negative binomial distribution in order to
take into account for over dispersion. Rates of bed days
per 100,000 children were calculated based on children
population figures from Statistics Finland available at
http://www.stat.fi/til/vaerak/tau_en.html.
The proportions of RV positive cases among all causes
AGE were also described per period and season and
trend in these proportions between the post- and pre-
vaccination periods was studied using a chi-squared test
for trend in proportions.
We compared the number of beds occupied for all
cause AGE and available beds per day, by estimating a
bed occupancy rate defined as the ratio between the
number of beds occupied for all cause AGE and the
number of available beds in Tampere (n = 16) and in
Oulu (n = 9). The bed occupancy rate was then stratifiedin 5 classes, 0-25%, 26-50%, 51-75%, 76-100% and >100%.
The distribution of days according to the defined bed
occupancy classes was compared between the post- and
pre-vaccination periods using a chi-squared test.
We extrapolated the results of this study to the whole
country by estimating the 2013 annual absolute number
of bed days and prevented bed days after the introduction
of the national RV program in Finland. For this, we pooled
the data of Tampere and Oulu by period (i.e. pre- and
post-vaccination) to calculate the rates (and its 95% CI) of
number of bed days and number of prevented bed days
per 100,000 children aged respectively 0–16 and 0–2.
Then, we applied these rates to the whole national pop-
ulation figures of children 0–16 and 0–2 years in 2013.
Population figures were extracted from Statistics Finland,
available at: http://www.stat.fi/til/vaerak/tau_en.html. Ana-
lyses were done using SAS, SPSS and R, and p-values <0.05
were considered as statistically significant.Results
In Tampere, the overall number of bed days per 100,000
0–2 year-old children for RV AGE decreased from 925 in
the pre-vaccination to 70 in the post-vaccination period
corresponding to a statistically significant reduction of
93% (95% CI 77%-98%) (Table 1). Similar results were
observed when enlarging the age group to children up to
16 years, with the overall number of bed days per 100,000
children for RV AGE decreasing from 220 to 31, corre-
sponding to a reduction of 86% (95% CI 66%-94%). For all
cause AGE, a lower decrease from 2,839 bed days per
100,000 children in the pre-vaccination era to 972 bed
days per 100,000 children in the post-vaccination era was
observed among 0-2y children, corresponding to a reduc-
tion of 66% (95% CI 49% to 77%) and from 886 to 440 bed
days per 100,000 children, thus a 50% reduction (95% CI
29% to 65%) among 0-16y children. Table 1 also presented
the corresponding absolute reduction of the number of
bed days per 100,000 children.
In Oulu, the average annual number of bed days for RV
AGE per 100,000 0–2 year -old children decreased from
1,017 in the pre-vaccination to 170 in the post-vaccination
period corresponding to a statistically significant reduc-
tion of 83% (95% CI 35%-96%) (Table 2). For 0–16 year-
old children, the average annual number of bed days per
100,000 children for RV AGE decreased from 261 to 54,
corresponding to a reduction of 79% (95% CI 47%-92%).
For all cause AGE, a lower decrease from 3,850 bed days
per 100,000 children in the pre-vaccination era to 757 bed
days per 100,000 children in the post-vaccination era
was observed among 0-2y children, corresponding to a
reduction of 80% (95% CI 68% to 88%) and from 1,233
to 365 bed days per 100,000 children, thus a 70% reduc-
tion (95% CI 58% to 79%) among 0-16y children. Table 2
Table 1 Number of bed days, reduction of the number of bed days for RV and all cause AGE, and proportion of RV among all cause AGE according to
vaccination period and season among 0-16y and 0-2y children in Tampere
Children 0–16 years Children 0–2 years
Period Years Number of
children in the
catchment area
Number of bed days* % RV among
all AGE
Number of
children in the
catchment area
Number of bed days* % RV among
all AGERV AGE All AGE RV AGE All AGE
Pre-vaccination
period
2001-2002 87,856 238 839 28.4 15,241 181 477 37.9
2002-2003 88,105 288 1098 26.2 15,361 185 563 32.9
2003-2004 88,112 197 561 35.1 15,719 174 379 45.9
2004-2005 88,373 165 614 26.9 16,237 140 375 37.3
2005-2006 88,485 80 793 10.1 16,698 53 456 11.6
Annual average - 193.6 781.0 24.8 - 146.6 450 32.6
Overall number of bed
days per 100,000 children
- 220 886 - 925 2839
Transition period 2006-2007 88,657 43 600 7.2 16,932 29 329 8.8
2007-2008 88,591 290 1010 28.7 17,201 189 574 32.9
2008-2009 88,799 191 688 27.8 17,502 128 345 37.1
Annual average - 174.7 766 22.8 - 115.3 416.0 27.7
Overall number of bed
days per 100,000 children
- 197 864 - 670 2417
Post-vaccination
period
2009-2010 88,919 18 417 4.3 17,655 9 163 5.5
2010-2011 89,322 60 495 12.1 17,637 28 257 10.9
2011-2012 90,046 6 269 2.2 17,798 0 96 0.0
Annual average - 28.0 393.7 7.1 - 12.3 172.0 7.2
Overall number of bed
days per 100,000 children
- 31 440 - 70 972
% reduction (95% CI) of the number of
bed days per 100,000 children between
the post- and pre-vaccination periods
−86 (−66;-94) −50 (−29;-65) −93 (−77;-98) −66 (−49;-77)
Absolute reduction (95% CI) of the number
of bed days per 100,000 children between
the post- and pre-vaccination periods
−188
(−173;-204)
−445
(−408;-483)
−855
(−785;-926)
−1867
(−1723;-2011)
*unless otherwise specified.
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Table 2 Number of bed days, reduction of the number of bed days for RV and all cause AGE, and proportion of RV among all cause AGE according to
vaccination period and season among 0-16y and 0-2y children in Oulu
Children 0–16 years Children 0–2 years
Period Years Number of
children in the
catchment area
Number of bed days* % RV among
all AGE
Number of
children in the
catchment area
Number of bed days* % RV among
all AGERV AGE All AGE RV AGE All AGE
Pre-vaccination period 2001-2002 83,846 207 861 24.0 15,161 142 483 29.4
2002-2003 83,668 260 1127 23.1 15,310 169 655 25.8
2003-2004 84,107 260 1056 24.6 15,818 216 633 34.1
2004-2005 84,443 151 733 20.6 16,274 109 429 25.4
2005-2006 84,870 219 1415 15.5 16,606 169 848 19.9
Annual average - 219.4 1038.4 21.1 - 161 609.6 26.4
Overall number of bed
days per 100,000 children
- 261 1233 - 1017 3850
Transition period 2006-2007 85,064 33 1241 2.7 16,903 25 671 3.7
2007-2008 85,257 84 840 10.0 16,906 31 387 8.0
2008-2009 85,683 161 787 20.5 17,145 115 425 27.1
Annual average - 92.7 956.0 2.7 - 57 494.3 11.5
Overall number of bed
days per 100,000 children
- 109 1120 - 336 2910
Post-vaccination period 2009-2010 86,144 116 433 26.8 17,312 84 221 38.0
2010-2011 86,498 13.0 222 5.9 17,315 2 70 2.9
2011-2012 87,264 11 294 3.7 17,285 2 102 2.0
Annual average - 46.7 316.3 14.8 - 29.3 131.0 22.4
Overall number of bed
days per 100,000 children
- 54 365 - 170 757
% reduction (95% CI) of the number of
bed days per 100,000 children between
the post- and pre-vaccination periods
−79 (−47;-92) −70 (−58;-79) −83 (−35;-96) −80 (−68;-88)
Absolute reduction (95% CI) of the
number of bed days per 100,000
children between the post- and
pre-vaccination periods
−207
(−189;-225)
−868
(−828;-909)
−847
(−769;-926)
−3092
(−2937;-3249)
*unless otherwise specified.
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the number of bed days per 100,000 children.
The proportion of RV positive cases among all cause
AGE was also significantly reduced in the post-vaccination
period compared to the pre-vaccination period in 0-16y
children and 0-2y children from Tampere (Table 1) and
in 0-16y children from Oulu (Table 2). The proportion
of RV positive cases among all cause AGE in 0-2y
children from Oulu did not significantly vary between
vaccination periods (22.4% vs 26.4%, p = 0.087) and this
was mainly due to the high proportion observed during
the 2009/10 season.
In both hospitals in Oulu and in Tampere, bed occu-
pancy for all cause AGE was significantly lower in the
post-vaccination period than in the pre-vaccination
period (Table 3, Figure 2). In Oulu, while bed occupancy
for all cause AGE was >25% during 774 (48%) days in
the pre-vaccination period, it decreased to 103 (9%) in
the post-vaccination period. In Tampere, these figures
were 235 (13%) in the pre-vaccination period and 12
(1%) in the post-vaccination period.
Table 4 shows the estimated national absolute number
of bed days and number of prevented bed days after the
introduction of the national RV immunization program
in Finland which prevented 6,219 (95% CI, 5,956-6,483)
bed days for all cause AGE for 0–16 year-old children
and 4,443 (95% CI, 4,252-4,633) for 0–2 year-old chil-
dren, leading to a number of bed days for all cause AGE
of 3,846 (95% CI, 3,682-4,009) for 0–16 year-old children
and of 1,552 (95% CI, 1,451-1,653) for 0–2 year-old
children in 2013.Table 3 Distribution of the number of days with bed occupan
all cause AGE in children 0–16 years in Oulu (9 beds) and Tam
Season Vaccination period Total
number
of days
Bed occupancy for all cause
in children 0–16 years in Ou
0-25% 26-50% 51-75%
2001-02 Pre-vaccination period 365 219 89 46
2002-03 Pre-vaccination period 365 196 79 41
2003-04 Pre-vaccination period 366 197 76 53
2004-05 Pre-vaccination period 365 247 78 21
2005-06 Pre-vaccination period 365 193 48 30
2006-07 Transition period 365 181 72 53
2007-08 Transition period 366 249 65 30
2008-09 Transition period 365 242 69 39
2009-10 Post-vaccination period 365 309 41 12
2010-11 Post-vaccination period 365 348 17 0
2011-12 Post-vaccination period 366 336 29 1
Total (%) Pre-vaccination period 1826 1052 (58) 370 (20) 191 (10)
Transition period 1096 672 (61) 206 (19) 122 (11)
Post-vaccination period 1096 993 (91) 87 (8) 13 (1)The average length of stay for all cause AGE decreased
significantly from 3.1 days in the pre-vaccination to
2.6 days in the post-vaccination period (p < 0.001) in
Tampere and from 2.8 days to 2.4 (p < 0.001) in Oulu.
Discussion
This study highlights the substantial impact of the
national RV vaccination program on the reduction of the
number of bed days for RV AGE and to a lesser extend
for all cause AGE in two Finnish hospitals. Reduction in
AGE hospitalizations non coded specifically as rotavirus
suggest that testing and coding practices may underesti-
mate the true rate of rotavirus hospitalizations as it has
been described elsewhere [22]. Additionally, the mean
length of hospital stay per episode decreased when
comparing pre-vaccination periods with post-vaccination
periods. Overall results suggest that universal vaccination
with RotaTeq® led to a dramatic decrease of hospital over-
crowding reducing the risk for nosocomial infections and
situations of hospital disruption with negative adverse
effects on the overall quality of patient care. These results
are supported by the vaccine-probe design that allowed
estimating the vaccine-preventable RV AGE and all AGE
incidence, and extrapolate these results at the nationwide
scale.
Our study presents some limitations. We cannot ex-
clude that not all patients were tested, as hospitalization
time may in some cases have been too short to allow
children producing stool during their stay at hospital.
When a laboratory result was not available at the time of
hospital discharge of a patient, the case could not becy of 0-25%, 26-50%, 51-75%, 76-100% and >100% for
pere (16 beds)
AGE
lu
Bed occupancy for all cause AGE
in children 0–16 years in Tampere
76-100% >100% 0-25% 26-50% 51-75% 76-100% >100%
11 0 324 38 3 0 0
37 12 273 75 17 0 0
33 7 347 19 0 0 0
18 1 337 26 2 0 0
47 47 310 44 10 1 0
47 12 343 22 0 0 0
12 10 301 48 11 3 3
14 1 329 35 1 0 0
2 1 357 8 0 0 0
0 0 361 4 0 0 0
0 0 366 0 0 0 0
146 (8) 67 (4) 1591 (87) 202 (11) 32 (2) 1 (0) 0 (0)
73 (7) 23 (2) 973 (89) 105 (10) 12 (1) 3 (0) 3 (0)
2 (0) 1 (0) 1084 (99) 12 (1) 0 (0) 0 (0) 0 (0)
Figure 2 Distribution of the number of days with bed occupancy of 0-25%, 26-50%, 51-75%, 76-100% and >100% for all cause AGE in
children 0–16 years in Oulu (9 beds) and Tampere (16 beds).
Hartwig et al. BMC Health Services Research 2014, 14:632 Page 7 of 9
http://www.biomedcentral.com/1472-6963/14/632recorded as RV AGE. Thus rotavirus as a cause for AGE
is likely to be underestimated. We conclude that the
reduction of the mean hospital length of stay could be
attributable to the rotavirus vaccination program but
cannot exclude that a modification of the hospital organ-
ization has occurred during the 10-year study period.
Variability was observed in the population-based rates of
severe rotavirus infections each year and this natural secu-
lar variability in rotavirus disease should be considered in
the assessment of the impact of the vaccine, as it has been
reported elsewhere [9,23,24]. This may explain the high
rates of RV AGE in the transition period and the first year
of the post vaccination period in the Oulu hospital.
In 2007 the Finnish National Institute for Health and
Welfare (THL) estimated that without vaccination about
2,400 hospital admissions, 3,600 hospital outpatient visits,
9,000 primary care physician consultations and 0.5 deaths
attributable to rotavirus would occur annually among
children under 5 years of age in Finland [25]. WhenTable 4 Estimation of the national number of bed days and t
of the national RV program in Finland. In 2013, national figu
children 0–2 years
Rates per 100,000 child
based on Tampere and
Children 0–16 years
Number of bed days
(95% confidence interval)
RV AGE 42 (37;48)
All AGE 403 (386;420)
Number of prevented bed days
(95% confidence interval)
RV AGE 197 (209;186)
All AGE 652 (625;680)extrapolating the results of this study to the whole coun-
try, we estimated that 6,129 and 4,443 bed days for all
cause AGE were prevented in 2013 by rotavirus vaccin-
ation in children 0–16 years and 0–2 years respectively.
Assuming a hospital length of stay of 2.7 days (Oulu:
2.6 days and Tampere: 2.8 days) in the post-vaccination
period, the annual number of prevented hospitalizations
for all cause AGE can be estimated at 1,646 and 2,303
admissions for 0–2 and 0–16 year-old children respect-
ively, thus confirming the assumptions made by Salo et al.
in 2007 [25] who estimated that universal rotavirus vac-
cination could prevent some 2,000 hospital admissions in
under five year-old children yearly.
Finland represents a privileged place to study RV disease
and the impact of RV vaccination due to the high burden
of RV and high vaccine uptake. It was one of the first
countries in Europe recommending rotavirus vaccination
in December 2007. In September 2009 it introduced uni-
versal rotavirus vaccination with exclusive use of thehe number of prevented bed days after the introduction
res were 953,547 for children 0–16 years and 179,244 for
ren in 2012
Oulu data
National estimates in 2013, after the
introduction of the national RV program
Children 0–2 years Children 0–16 years Children 0–2 years
119 (98;140) 404 (352;458) 213 (176;251)
866 (809;922) 3,846 (3682;4009) 1,552 (1451;1653)
852 (799;905) 1,880 (1769;1992) 1,527 (1432;1621)
2,479 (2372;2585) 6,219 (5956;6483) 4,443 (4252;4633)
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RotaTeq® and following a vaccination schedule at age 2,
3 and 5 months reaching coverage rates of about 96%
for the vaccines included in the NIP. In Finland, the RV
related burden of disease was extensively studied through
observational studies [26-28] and through data collected
during the clinical development of rotavirus vaccines
[2,29-32].
The impact of RV vaccination on the number of
hospitalization was reported previously [11,32-36]. The
present study describes that RV vaccination can also
reduce seasonal hospital overcrowding due to RV AGE
during winter epidemics by assessing the reduction in
the number of occupied beds per day. While RV AGE
hospitalization only describes the number of patients
presenting at hospital with RVAGE, bed occupancy rather
reflects the pressure that hospitals and health care workers
face every day and specifically in periods of overlapping
winter epidemics. Overcrowding occurs when new admis-
sions for RV AGE exceed discharge of recovered patients,
with adverse consequences such as lower quality of care
[15], increased risk of nosocomial transmission among
patients and healthcare workers (HCWs) [37,38], work
stress [37-40], which may lead to hospital disruption with
unsolved ethical and organizational issues [3,41-43].
We used bed occupancy to estimate crowding due to
all cause AGE in children 0–16 year-old. While several
indicators have been studied to estimate emergency de-
partment crowding with NEDOCS and EDWIN [16-19],
no consensus and no indicators have been developed to
measure hospital disruption. It may be reasonable to think
that high occupancy rates (e.g. >50%) are associated with
hospital disruption and impaired care. In addition to that
a previous study conducted in a ward for paediatric infec-
tious diseases at the Hospital of Oulu identified room
sharing as one of the factors increasing the risk of hospital
acquired infections [44].
Conclusions
In conclusion, this study demonstrated that universal RV
vaccination is associated with a clear decrease in the
number of bed days and occupancy rates for RV AGE
and all cause AGE. As a consequence, it is expected that
RV vaccination increases quality of care by allowing a bet-
ter management of overlapping winter epidemics, such as
bronchiolitis or influenza and by decreasing associated
costs for healthcare institutions.
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